Lisa D. Earnhardt - 24 Feb 2026 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EVP AND GROUP PRESIDENT
Signature
/s/ Lisa D. Earnhardt, by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
24 Feb 2026
Net transactions value
$0
Form type
4
Filing time
26 Feb 2026, 18:11:42 UTC
Previous filing
07 Mar 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Earnhardt Lisa D EVP AND GROUP PRESIDENT 100 ABBOTT PARK ROAD, ABBOTT PARK /s/ Lisa D. Earnhardt, by Jessica H. Paik, Attorney-in-Fact 26 Feb 2026 0001530893

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +27,056 +38% $0.000000 98,984 24 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +111,533 $0.000000 111,533 24 Feb 2026 Common Shares 111,533 $114.60 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 37,177 on February 24, 2027, 37,178 on February 24, 2028, and 37,178 on February 24, 2029.